Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.10
AFFX's Cash to Debt is ranked lower than
62% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. AFFX: 1.10 )
Ranked among companies with meaningful Cash to Debt only.
AFFX' s Cash to Debt Range Over the Past 10 Years
Min: 0.15  Med: 1.19 Max: No Debt
Current: 1.1
Equity to Asset 0.61
AFFX's Equity to Asset is ranked higher than
50% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. AFFX: 0.61 )
Ranked among companies with meaningful Equity to Asset only.
AFFX' s Equity to Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.55 Max: 0.95
Current: 0.61
0.19
0.95
Interest Coverage 3.11
AFFX's Interest Coverage is ranked lower than
88% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 166.12 vs. AFFX: 3.11 )
Ranked among companies with meaningful Interest Coverage only.
AFFX' s Interest Coverage Range Over the Past 10 Years
Min: 0.33  Med: 1.89 Max: 37.16
Current: 3.11
0.33
37.16
F-Score: 8
Z-Score: 3.00
M-Score: -2.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 5.06
AFFX's Operating margin (%) is ranked higher than
59% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. AFFX: 5.06 )
Ranked among companies with meaningful Operating margin (%) only.
AFFX' s Operating margin (%) Range Over the Past 10 Years
Min: -59.12  Med: -4.51 Max: 15.62
Current: 5.06
-59.12
15.62
Net-margin (%) 3.14
AFFX's Net-margin (%) is ranked higher than
60% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. AFFX: 3.14 )
Ranked among companies with meaningful Net-margin (%) only.
AFFX' s Net-margin (%) Range Over the Past 10 Years
Min: -75.06  Med: -3.74 Max: 17.9
Current: 3.14
-75.06
17.9
ROE (%) 3.72
AFFX's ROE (%) is ranked higher than
57% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. AFFX: 3.72 )
Ranked among companies with meaningful ROE (%) only.
AFFX' s ROE (%) Range Over the Past 10 Years
Min: -68.27  Med: -3.67 Max: 16.93
Current: 3.72
-68.27
16.93
ROA (%) 2.20
AFFX's ROA (%) is ranked higher than
60% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. AFFX: 2.20 )
Ranked among companies with meaningful ROA (%) only.
AFFX' s ROA (%) Range Over the Past 10 Years
Min: -33.34  Med: -2.03 Max: 10.32
Current: 2.2
-33.34
10.32
ROC (Joel Greenblatt) (%) 24.16
AFFX's ROC (Joel Greenblatt) (%) is ranked higher than
71% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. AFFX: 24.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AFFX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -120.45  Med: -2.66 Max: 54.6
Current: 24.16
-120.45
54.6
Revenue Growth (3Y)(%) 8.20
AFFX's Revenue Growth (3Y)(%) is ranked higher than
63% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.70 vs. AFFX: 8.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AFFX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -33.6  Med: 5.35 Max: 102.9
Current: 8.2
-33.6
102.9
EBITDA Growth (3Y)(%) 52.40
AFFX's EBITDA Growth (3Y)(%) is ranked higher than
94% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. AFFX: 52.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AFFX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -24.4  Med: -2.95 Max: 52.4
Current: 52.4
-24.4
52.4
EPS Growth (3Y)(%) -49.20
AFFX's EPS Growth (3Y)(%) is ranked lower than
87% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. AFFX: -49.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AFFX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -55.5  Med: -10.40 Max: 25.2
Current: -49.2
-55.5
25.2
» AFFX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

AFFX Guru Trades in Q1 2015

Jim Simons 1,346,823 sh (+376.55%)
Paul Tudor Jones 38,200 sh (+24.25%)
PRIMECAP Management 11,037,040 sh (+0.89%)
Murray Stahl 104,000 sh (unchged)
Chuck Royce 4,000 sh (unchged)
Joel Greenblatt Sold Out
» More
Q2 2015

AFFX Guru Trades in Q2 2015

Jim Simons 2,153,623 sh (+59.90%)
Murray Stahl 104,000 sh (unchged)
Chuck Royce 4,000 sh (unchged)
PRIMECAP Management 11,014,740 sh (-0.20%)
Paul Tudor Jones 30,700 sh (-19.63%)
» More
Q3 2015

AFFX Guru Trades in Q3 2015

Ken Fisher 352,394 sh (New)
Steven Cohen 323,600 sh (New)
Joel Greenblatt 49,493 sh (New)
Jim Simons 2,463,923 sh (+14.41%)
Chuck Royce 4,000 sh (unchged)
Murray Stahl 104,000 sh (unchged)
PRIMECAP Management 10,856,540 sh (-1.44%)
Paul Tudor Jones 25,100 sh (-18.24%)
» More
Q4 2015

AFFX Guru Trades in Q4 2015

Ken Fisher 379,737 sh (+7.76%)
» More
» Details

Insider Trades

Latest Guru Trades with AFFX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 100.32
AFFX's P/E(ttm) is ranked lower than
93% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.91 vs. AFFX: 100.32 )
Ranked among companies with meaningful P/E(ttm) only.
AFFX' s P/E(ttm) Range Over the Past 10 Years
Min: 11.36  Med: 53.74 Max: 971
Current: 100.32
11.36
971
Forward P/E 28.90
AFFX's Forward P/E is ranked lower than
79% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.38 vs. AFFX: 28.90 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 108.01
AFFX's PE(NRI) is ranked lower than
94% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.80 vs. AFFX: 108.01 )
Ranked among companies with meaningful PE(NRI) only.
AFFX' s PE(NRI) Range Over the Past 10 Years
Min: 11.71  Med: 55.43 Max: 971
Current: 108.01
11.71
971
P/B 3.41
AFFX's P/B is ranked lower than
62% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.57 vs. AFFX: 3.41 )
Ranked among companies with meaningful P/B only.
AFFX' s P/B Range Over the Past 10 Years
Min: 0.24  Med: 1.95 Max: 11.78
Current: 3.41
0.24
11.78
P/S 3.12
AFFX's P/S is ranked lower than
65% of the 243 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. AFFX: 3.12 )
Ranked among companies with meaningful P/S only.
AFFX' s P/S Range Over the Past 10 Years
Min: 0.38  Med: 1.74 Max: 11.22
Current: 3.12
0.38
11.22
PFCF 30.56
AFFX's PFCF is ranked lower than
55% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.13 vs. AFFX: 30.56 )
Ranked among companies with meaningful PFCF only.
AFFX' s PFCF Range Over the Past 10 Years
Min: 1.89  Med: 17.95 Max: 1220.5
Current: 30.56
1.89
1220.5
POCF 23.01
AFFX's POCF is ranked lower than
58% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.16 vs. AFFX: 23.01 )
Ranked among companies with meaningful POCF only.
AFFX' s POCF Range Over the Past 10 Years
Min: 1.64  Med: 18.09 Max: 2657
Current: 23.01
1.64
2657
EV-to-EBIT 62.67
AFFX's EV-to-EBIT is ranked lower than
92% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.49 vs. AFFX: 62.67 )
Ranked among companies with meaningful EV-to-EBIT only.
AFFX' s EV-to-EBIT Range Over the Past 10 Years
Min: -998  Med: 4.30 Max: 721.4
Current: 62.67
-998
721.4
EV-to-EBITDA 27.16
AFFX's EV-to-EBITDA is ranked lower than
85% of the 176 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.68 vs. AFFX: 27.16 )
Ranked among companies with meaningful EV-to-EBITDA only.
AFFX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -129.2  Med: 17.60 Max: 112.9
Current: 27.16
-129.2
112.9
Current Ratio 3.54
AFFX's Current Ratio is ranked higher than
59% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. AFFX: 3.54 )
Ranked among companies with meaningful Current Ratio only.
AFFX' s Current Ratio Range Over the Past 10 Years
Min: 1.52  Med: 5.22 Max: 23.52
Current: 3.54
1.52
23.52
Quick Ratio 2.79
AFFX's Quick Ratio is ranked higher than
55% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. AFFX: 2.79 )
Ranked among companies with meaningful Quick Ratio only.
AFFX' s Quick Ratio Range Over the Past 10 Years
Min: 1.25  Med: 4.94 Max: 23.21
Current: 2.79
1.25
23.21
Days Inventory 144.74
AFFX's Days Inventory is ranked lower than
72% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. AFFX: 144.74 )
Ranked among companies with meaningful Days Inventory only.
AFFX' s Days Inventory Range Over the Past 10 Years
Min: 97.14  Med: 133.55 Max: 159.76
Current: 144.74
97.14
159.76
Days Sales Outstanding 48.82
AFFX's Days Sales Outstanding is ranked higher than
70% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. AFFX: 48.82 )
Ranked among companies with meaningful Days Sales Outstanding only.
AFFX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.04  Med: 63.98 Max: 96.42
Current: 48.82
49.04
96.42

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 31.20
AFFX's Price/Net Current Asset Value is ranked lower than
91% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.70 vs. AFFX: 31.20 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AFFX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.9  Med: 12.72 Max: 419.8
Current: 31.2
1.9
419.8
Price/Tangible Book 15.95
AFFX's Price/Tangible Book is ranked lower than
86% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.71 vs. AFFX: 15.95 )
Ranked among companies with meaningful Price/Tangible Book only.
AFFX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.87  Med: 9.30 Max: 75.92
Current: 15.95
0.87
75.92
Price/Projected FCF 2.03
AFFX's Price/Projected FCF is ranked higher than
50% of the 112 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.03 vs. AFFX: 2.03 )
Ranked among companies with meaningful Price/Projected FCF only.
AFFX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.42  Med: 1.44 Max: 219.36
Current: 2.03
0.42
219.36
Price/Median PS Value 1.85
AFFX's Price/Median PS Value is ranked lower than
92% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.95 vs. AFFX: 1.85 )
Ranked among companies with meaningful Price/Median PS Value only.
AFFX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.31  Med: 2.71 Max: 38.98
Current: 1.85
0.31
38.98
Price/Graham Number 8.78
AFFX's Price/Graham Number is ranked lower than
88% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. AFFX: 8.78 )
Ranked among companies with meaningful Price/Graham Number only.
AFFX' s Price/Graham Number Range Over the Past 10 Years
Min: 1.07  Med: 5.48 Max: 16.2
Current: 8.78
1.07
16.2
Earnings Yield (Greenblatt) (%) 1.62
AFFX's Earnings Yield (Greenblatt) (%) is ranked higher than
51% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. AFFX: 1.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AFFX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 2.00 Max: 526.4
Current: 1.62
0.1
526.4
Forward Rate of Return (Yacktman) (%) -8.92
AFFX's Forward Rate of Return (Yacktman) (%) is ranked lower than
91% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.03 vs. AFFX: -8.92 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
AFFX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -16.6  Med: 2.60 Max: 12.2
Current: -8.92
-16.6
12.2

More Statistics

Revenue(Mil) $358
EPS $ 0.14
Beta-0.72
Short Percentage of Float12.77%
52-Week Range $8.28 - 14.13
Shares Outstanding(Mil)79.97

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 358 372 387
EPS($) 0.42 0.44 0.49
EPS without NRI($) 0.42 0.44 0.49

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:AFF.Germany,
Affymetrix Inc was incorporated in California in 1992 and reincorporated in Delaware in 1998. The Company is a provider of life science tools and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. It sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. The Companys operations consist of two reportable segments, Affymetrix Core and eBioscience. Affymetrix Core is divided into three business units with each business unit having its own research, development and marketing groups to better serve customers and respond quickly to the market needs. The three business units that form Affymetrix Core are; Expression, Genetic Analysis and Clinical Applications, and Life Science Reagents. Expression: This business unit develops and markets the Company's GeneChip gene expression products and services, and the QuantiGene line of low-to-mid-plex RNA measurement products; Genetic Analysis and Clinical Applications. This business unit develops and markets the Company's genotyping, such as the Axiom product line and clinical research applications, such as the CytoScan cytogenetics; Life Science Reagents; This business unit develops and sells reagents, enzymes, purification kits and biochemicals used by life science researchers. eBioscience; This reportable segment specializes in the development, manufacturing, marketing and distribution of research tools in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company markets and distributes its products directly to customers in North America, Japan and major European markets. The Company is facing competition as existing companies develop new or improved products, and as companies enter the market with new technologies, such as next-generation sequencing. In the highly multiplexed genotyping and gene expression markets, existing competitive technologies include DNA sequencing, which the Company does not offer and is offered by companies such as Illumina, Inc., Life Technologies Corporation and Pacific Biosciences of California, Inc. The Companys operations are subject to complex and stringent environmental, health, safety and other governmental laws and regulations.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK